Please check back frequently for company news and new peer-reviewed scientific publications featuring the Vala platform.
Vala Sciences attended the Society for Neuroscience annual meeting in Washington, DC! Director of Neurobiology Kara Gordon and Research Scientist Christine Rines presented three posters:
2D and 3D iPSC-derived platforms for neurotoxicity screening demonstrate compound effects on calcium activity, synapses, viability and cell proliferation View here
Anti-retroviral therapy is toxic to iPSC-derived NPC’s in vitro and alters neuronal calcium transients in differentiated NPCs View here
“Epilepsy in a dish” (EIDA): a suite of assays to discover therapeutics of epilepsy using isogenic hiPSC-neuron/astrocyte/microglia 2D and 3D tri-cultures and kinetic imaging cytometry View here
Vala Sciences Inc. and Anatomic Incorporated have been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences (NCATS).
Project title: “The Pain in a Dish Assay (PIDA): a high throughput system featuring human stem cell-derived nociceptors and dorsal horn neurons to test compounds for analgesic activity” (NIH/NCATS R43 TR004743-01)
The Pain in a Dish Assay will combine our high content screening technology with Anatomic’s hiPSC-derived pain models to find new, more effective pain treatments.
Ranor Basa, our Director of Assay Development, presented a poster at the American Heart Association Basic Cardiovascular Sciences meeting in Boston.
Poster title: “Multiplexed Cardiotoxicity And Efficacy Screening Using Kinetic Image Cytometry Of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes”
Ranor’s poster highlighted the application of our Kinetic Image Cytometry® high content imaging technology to quantify drug effects on voltage action potentials, calcium transients, and contractile motion in hiPSC-cardiomyocytes.
Conference: Vala Sciences will be at SLAS 2022 in Boston!
Patrick M. McDonough, Ph.D., Vala’s Chief Research Officer, will give a podium presentation in the Advanced Imaging and High Content Assays session on Monday, February 7 at 10:30am. Presentation title: High-content analysis and Kinetic Image Cytometry identify toxic and epigenotoxic effects of HIV antiretrovirals on human iPSC-neurons and neural precursor cells Read more about this research here.
Jeffrey H. Price, M.D., Ph.D., Vala’s Founder, President, and CEO, will present a poster on Tuesday, February 8, 11:30am- 12:30pm. Poster title: Artificial Intelligence Augmented Multiplexed Cardiomyopathy and Proarrhythmia in vitro Assay of Stem Cell Cardiomyocytes for Early Drug Development
November 4, 2021
Video: Kara L. Gordon, Ph.D., Vala’s Director of Neurobiology, spoke in an Elixirgen Scientific webinar, highlighting Vala’s innovations using hiPSCs in CNS drug discovery and neurotoxicity screening, including imaging using KIC® and image analysis using CyteSeer®. Watch the webinar to learn more about the latest applications of Vala’s technology to study HIV antiretroviral neurotoxicity. Read a summary of the webinar here.
Video: Paul Burridge, PhD, assistant professor of Pharmacology at Northwestern University, uses Vala’s KIC® platform to study how a patient’s genetics cause negative responses such as cardiotoxicity to chemotherapy agents.